Orchestrating immune check-point blockade for cancer immunotherapy in combinations

Current Opinion in Immunology

Volumn 27, Issue 1, 2014, Pages 89-97

  Perez Gracia, Jose Luis ^a   Labiano, Sara ^a   Rodriguez Ruiz, Maria E ^a   Sanmamed, Miguel F ^a   Melero, Ignacio ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; IPILIMUMAB; MEMBRANE PROTEIN; MK 3475; MPDL3280A; NIVOLUMAB; PIDILIZUMAB; PLACEBO; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN LAG 3; PROTEIN TIM 3; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELL CYCLE CHECKPOINT; CELL FUNCTION; COLITIS; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; INTERSTITIAL PNEUMONIA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PANCREAS CARCINOMA; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; RASH; REVIEW; SOLID TUMOR; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TRANSITIONAL CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTES;

EID: 84897041811     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.002     Document Type: Review

References (108)

1. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev: Immunol 2013, 13:227-242.
2. Acuto O., Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat Rev: Immunol 2003, 3:939-951.
3. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev: Cancer 2012, 12:252-264.
4. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev: Cancer 2007, 7:95-106.
5. Melero I., Grimaldi A.M., Perez-Gracia J.L., Ascierto P.A. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res: Off J Am Assoc Cancer Res 2013, 19:997-1008.
6. Brunet J.F., Denizot F., Luciani M.F., Roux-Dosseto M., Suzan M., Mattei M.G., Golstein P. A new member of the immunoglobulin superfamily - CTLA-4. Nature 1987, 328:267-270.
7. Linsley P.S., Brady W., Urnes M., Grosmaire L.S., Damle N.K., Ledbetter J.A. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991, 174:561-569.
8. Leung H.T., Bradshaw J., Cleaveland J.S., Linsley P.S. Cytotoxic T lymphocyte-associated molecule-4, a high-avidity receptor for CD80 and CD86, contains an intracellular localization motif in its cytoplasmic tail. J Biol Chem 1995, 270:25107-25114.
9. Linsley P.S., Bradshaw J., Greene J., Peach R., Bennett K.L., Mittler R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996, 4:535-543.
10. Pentcheva-Hoang T., Egen J.G., Wojnoonski K., Allison J.P. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004, 21:401-413.
11. Takahashi T., Tagami T., Yamazaki S., Uede T., Shimizu J., Sakaguchi N., Mak T.W., Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000, 192:303-310.
12. Hu H., Djuretic I., Sundrud M.S., Rao A. Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT. Trends Immunol 2007, 28:329-332.
13. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., Bates D.L., Guo L., Han A., Ziegler S.F., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
14. Linsley P.S., Greene J.L., Tan P., Bradshaw J., Ledbetter J.A., Anasetti C., Damle N.K. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med 1992, 176:1595-1604.
15. Krummel M.F., Allison J.P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
16. Krummel M.F., Allison J.P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996, 183:2533-2540.
17. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
18. Mandelbrot D.A., McAdam A.J., Sharpe A.H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J Exp Med 1999, 189:435-440.
19. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995, 3:541-547.
20. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., Nomura T., Sakaguchi S. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
21. van der Merwe P.A., Bodian D.L., Daenke S., Linsley P., Davis S.J. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997, 185:393-403.
22. Mandelbrot D.A., Oosterwegel M.A., Shimizu K., Yamada A., Freeman G.J., Mitchell R.N., Sayegh M.H., Sharpe A.H. B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. J Clin Investig 2001, 107:881-887.
23. Marengere L.E., Waterhouse P., Duncan G.S., Mittrucker H.W., Feng G.S., Mak T.W. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996, 272:1170-1173.
24. Lee K.M., Chuang E., Griffin M., Khattri R., Hong D.K., Zhang W., Straus D., Samelson L.E., Thompson C.B., Bluestone J.A. Molecular basis of T cell inactivation by CTLA-4. Science 1998, 282:2263-2266.
25. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., Baker J., Jeffery L.E., Kaur S., Briggs Z., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
26. Schneider H., Downey J., Smith A., Zinselmeyer B.H., Rush C., Brewer J.M., Wei B., Hogg N., Garside P., Rudd C.E. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975.
27. Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000, 192:295-302.
28. Corse E., Allison J.P. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J Immunol 2012, 189:1123-1127.
29. Ishida Y., Agata Y., Shibahara K., Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992, 11:3887-3895.
30. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
31. Benson D.M., Bakan C.E., Mishra A., Hofmeister C.C., Efebera Y., Becknell B., Baiocchi R.A., Zhang J., Yu J., Smith M.K., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010, 116:2286-2294.
32. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
33. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
34. Okazaki T., Tanaka Y., Nishio R., Mitsuiye T., Mizoguchi A., Wang J., Ishida M., Hiai H., Matsumori A., Minato N., et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med 2003, 9:1477-1483.
35. Dong H., Zhu G., Tamada K., Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
36. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
37. Tseng S.Y., Otsuji M., Gorski K., Huang X., Slansky J.E., Pai S.I., Shalabi A., Shin T., Pardoll D.M., Tsuchiya H. B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193:839-846.
38. Latchman Y., Wood C.R., Chernova T., Chaudhary D., Borde M., Chernova I., Iwai Y., Long A.J., Brown J.A., Nunes R., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
39. Lee S.J., Jang B.C., Lee S.W., Yang Y.I., Suh S.I., Park Y.M., Oh S., Shin J.G., Yao S., Chen L., et al. Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 2006, 580:755-762.
40. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
41. Muhlbauer M., Fleck M., Schutz C., Weiss T., Froh M., Blank C., Scholmerich J., Hellerbrand C. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol 2006, 45:520-528.
42. Okazaki T., Maeda A., Nishimura H., Kurosaki T., Honjo T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 2001, 98:13866-13871.
43. Chemnitz J.M., Parry R.V., Nichols K.E., June C.H., Riley J.L. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 2004, 173:945-954.
44. Saunders P.A., Hendrycks V.R., Lidinsky W.A., Woods M.L. PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. Eur J Immunol 2005, 35:3561-3569.
45. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012, 209:1201-1217.
46. Wei F., Zhong S., Ma Z., Kong H., Medvec A., Ahmed R., Freeman G.J., Krogsgaard M., Riley J.L. Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci U S A 2013, 110:E2480-E2489.
47. Riley J.L. PD-1 signaling in primary T cells. Immunol Rev 2009, 229:114-125.
48. Zinselmeyer B.H., Heydari S., Sacristan C., Nayak D., Cammer M., Herz J., Cheng X., Davis S.J., Dustin M.L., McGavern D.B. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J Exp Med 2013, 210:757-774.
49. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
50. Jin H.T., Ahmed R., Okazaki T. Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 2011, 350:17-37.
51. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
52. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., DePierres C., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
53. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G., Ferrari C. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
54. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D.B., Lau J.S., Zhu G., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005, 65:1089-1096.
55. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134:392-404.
56. Ouyang W., Rutz S., Crellin N.K., Valdez P.A., Hymowitz S.G. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011, 29:71-109.
57. Baixeras E., Huard B., Miossec C., Jitsukawa S., Martin M., Hercend T., Auffray C., Triebel F., Piatier-Tonneau D. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med 1992, 176:327-337.
58. Hannier S., Tournier M., Bismuth G., Triebel F. CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol 1998, 161:4058-4065.
59. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
60. Zhu C., Anderson A.C., Kuchroo V.K. TIM-3 and its regulatory role in immune responses. Curr Top Microbiol Immunol 2011, 350:1-15.
61. + T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Investig 2007, 117:3383-3392.
62. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
63. + T cell dysfunction in melanoma patients. J Exp Med 2010, 207:2175-2186.
64. Heusschen R., Griffioen A.W., Thijssen V.L. Galectin-9 in tumor biology: a jack of multiple trades. Biochim Biophys Acta 2013, 1836:177-185.
65. + T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat Immunol 2009, 10:29-37.
66. Goldberg M.V., Drake C.G. LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011, 344:269-278.
67. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Olive D., Kuchroo V., Zarour H.M. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72:887-896.
68. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
69. van Elsas A., Hurwitz A.A., Allison J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999, 190:355-366.
70. Peggs K.S., Quezada S.A., Chambers C.A., Korman A.J., Allison J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.
71. Onishi Y., Fehervari Z., Yamaguchi T., Sakaguchi S. Foxp3+ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc Natl Acad Sci U S A 2008, 105:10113-10118.
72. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013, 210:1695-1710.
73. Wolchok J.D., Hodi F.S., Weber J.S., Allison J.P., Urba W.J., Robert C., O'Day S.J., Hoos A., Humphrey R., Berman D.M., et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci 2013, 1291:1-13.
74. Ribas A. Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol 2010, 37:450-454.
75. Ribas A., Camacho L.H., Lopez-Berestein G., Pavlov D., Bulanhagui C.A., Millham R., Comin-Anduix B., Reuben J.M., Seja E., Parker C.A., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol: Off J Am Soc Clin Oncol 2005, 23:8968-8977.
76. Hoos A., Ibrahim R., Korman A., Abdallah K., Berman D., Shahabi V., Chin K., Canetta R., Humphrey R. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 2010, 37:533-546.
77. Ribas A., Comin-Anduix B., Economou J.S., Donahue T.R., de la Rocha P., Morris L.F., Jalil J., Dissette V.B., Shintaku I.P., Glaspy J.A., et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res: Off J Am Assoc Cancer Res 2009, 15:390-399.
78. Hodi F.S., Butler M., Oble D.A., Seiden M.V., Haluska F.G., Kruse A., Macrae S., Nelson M., Canning C., Lowy I., et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008, 105:3005-3010.
79. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100:4712-4717.
80. Fecher L.A., Agarwala S.S., Hodi F.S., Weber J.S. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013, 18:733-743.
81. Maio M., Danielli R., Chiarion-Sileni V., Pigozzo J., Parmiani G., Ridolfi R., De Rosa F., Del Vecchio M., Di Guardo L., Queirolo P., et al. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2013, 24:2911-2915.
82. Voskens C.J., Goldinger S.M., Loquai C., Robert C., Kaehler K.C., Berking C., Bergmann T., Bockmeyer C.L., Eigentler T., Fluck M., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013, 8:e53745.
83. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
84. Hamid O., Schmidt H., Nissan A., Ridolfi L., Aamdal S., Hansson J., Guida M., Hyams D.M., Gomez H., Bastholt L., et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med 2011, 9:204.
85. Callahan M.K., Wolchok J.D., Allison J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol 2010, 37:473-484.
86. Ku G.Y., Yuan J., Page D.B., Schroeder S.E., Panageas K.S., Carvajal R.D., Chapman P.B., Schwartz G.K., Allison J.P., Wolchok J.D. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010, 116:1767-1775.
87. Fu T., He Q., Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011, 71:5445-5454.
88. Robert C., Thomas L., Bondarenko I., O'Day S., DJ M., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
89. Prieto P.A., Yang J.C., Sherry R.M., Hughes M.S., Kammula U.S., White D.E., Levy C.L., Rosenberg S.A., Phan G.Q. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2012, 18:2039-2047.
90. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Neal J., Lu H., Cuillerot J.M., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol: Off J Am Soc Clin Oncol 2012, 30:2046-2054.
91. Hurwitz A.A., Foster B.A., Kwon E.D., Truong T., Choi E.M., Greenberg N.M., Burg M.B., Allison J.P. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000, 60:2444-2448.
92. Small E.J., Tchekmedyian N.S., Rini B.I., Fong L., Lowy I., Allison J.P. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res: Off J Am Assoc Cancer Res 2007, 13:1810-1815.
93. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., Garbe C., Gogas H., Schachter J., Linette G., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol: Off J Am Soc Clin Oncol 2013, 31:616-622.
94. Sangro B., Gomez-Martin C., de la Mata M., Inarrairaegui M., Garralda E., Barrera P., Riezu-Boj J.I., Larrea E., Alfaro C., Sarobe P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013, 59:81-88.
95. Sznol M., Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer - response. Clin Cancer Res: Off J Am Assoc Cancer Res 2013, 19:5542.
96. Pardoll D.M. Immunology beats cancer: a blueprint for successful translation. Nat Immunol 2012, 13:1129-1132.
97. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol: Off J Am Soc Clin Oncol 2010, 28:3167-3175.
98. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
99. Lipson E.J., Sharfman W.H., Drake C.G., Wollner I., Taube J.M., Anders R.A., Xu H., Yao S., Pons A., Chen L., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res: Off J Am Assoc Cancer Res 2013, 19:462-468.
100. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
101. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369:134-144.
102. Demaria S., Pilones K.A., Formenti S.C., Dustin M.L. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology 2013, 2:e23127.
103. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
104. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
105. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
106. Takeda K., Kojima Y., Uno T., Hayakawa Y., Teng M.W., Yoshizawa H., Yagita H., Gejyo F., Okumura K., Smyth M.J. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J Immunol 2010, 184:5493-5501.
107. Morales-Kastresana A., Sanmamed M.F., Rodriguez I., Palazon A., Martinez-Forero I., Labiano S., Hervas-Stubbs S., Sangro B., Ochoa C., Rouzaut A., et al. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res: Off J Am Assoc Cancer Res 2013, 19:6151-6162.
108. John L.B., Devaud C., Duong C.P., Yong C.S., Beavis P.A., Haynes N.M., Chow M.T., Smyth M.J., Kershaw M.H., Darcy P.K. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res: Off J Am Assoc Cancer Res 2013, 19:5636-5646.